Mohamad Faizal Bin Ramli
Numerous Highlights from Q4 Earnings
- Novo Nordisk has reported a Q4 GAAP EPS of DKK 4.91.
- The revenue stands at an impressive DKK 65.86 billion, marking a 37.0% Y/Y growth.
- Sales within Diabetes and Obesity care have seen significant strides, increasing by 38% in Danish kroner to DKK 215.1 billion (42% at CER).
Outlook Initiatives for 2024
The future outlook of Novo Nordisk encompasses ambitious targets for 2024, showcasing a strong stance for continued growth and innovation.
- Sales growth at CER is projected to be in the range of 18% to 26% as reported, slightly lower than at CER.
- Operating profit growth at CER is estimated to be between 21% to 29% as reported, further showing promising prospects.
- The financial items (net) gain is expected to reach around DKK 1.3 billion, indicating a robust financial position.
- Additionally, the effective tax rate is forecasted to be within the range of 19% to 21%, reflecting prudent financial management.
- Capital expenditure (PP&E) is to be around DKK 45 billion, a significant investment in future growth and sustainability.
- Furthermore, Novo Nordisk anticipates free cash flow (excluding impact from business development) in the range of DKK 64-74 billion, demonstrating strong financial performance.
